Telo Genomics (TSXV:TELO) Interest Expense : C$0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Telo Genomics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Telo Genomics's interest expense for the three months ended in Sep. 2024 was C$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Telo Genomics's Operating Income for the three months ended in Sep. 2024 was C$ -0.55 Mil. Telo Genomics's Interest Expense for the three months ended in Sep. 2024 was C$ 0.00 Mil. Telo Genomics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Telo Genomics Interest Expense Historical Data

The historical data trend for Telo Genomics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telo Genomics Interest Expense Chart

Telo Genomics Annual Data

Trend

Dec14

Dec15

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Interest Expense

Get a 7-Day Free Trial

-0.03

Telo Genomics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Telo Genomics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Telo Genomics (TSXV:TELO) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Telo Genomics's Interest Expense for the three months ended in Sep. 2024 was C$0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was C$-0.55 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was C$0.00 Mil.

Telo Genomics's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Telo Genomics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Telo Genomics Corp has enough cash to cover all of its debt. Its financial situation is stable.

Telo Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Telo Genomics Corp (TSXV:TELO) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

TDSGF:USA

Address

101 College Street, Suite 200, MaRS Centre, South Tower, Toronto, ON, CAN, M5G 1L7

Website

https://www.telodx.com

Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.

Executives